Andere Sprachen Gritstone bio, Inc.

Aktien

A2N4RX

US39868T1051

GRTS

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 25.04.2024			% 5 Tage	% 1. Jan.
0,7645 ^USD	-5,95 %		+2,80 %	-62,52 %

15.04.	Nature Medicine veröffentlicht Zwischenergebnisse der Phase-1/2-Studie von Gritstone Bio mit der Neoantigen-Impfstoff-Plattform SLATE (Off-The-Shelf)	CI
02.04.	Top-Mittagsverlierer	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS	20.04.
Nature Medicine Publishes Interim Results from Gritstone bio's Phase 1/2 Study of 'Off-the-Shelf' Neoantigen Vaccine Platform	16.04.
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)	15.04.
Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform	15.04.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS	12.04.
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences	08.04.
Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024	08.04.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS	05.04.
Top Midday Decliners	02.04.
Gritstone bio Prices $32.5 Million Public Offering of Stock, Warrants	02.04.
Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering	02.04.
Gritstone Bio Discloses Preliminary Progression-Free Survival Data From Colorectal Cancer Vaccine Trial; Shares Fall	01.04.
Gritstone Bio Starts Public Offering; Shares Drop After-Hours	01.04.
Gritstone bio Announces Proposed Public Offering	01.04.
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)	01.04.
Gritstone Bio, Inc. Announces Positive Preliminary Progression-Free Survival and Long-Term Circulating Tumor DNA Data from Phase 2/3 Study of its Personalized Cancer Vaccine, Granite, Granite, Granite	01.04.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS	19.03.
Earnings Flash (GRTS) GRITSTONE BIO Posts Q4 Revenue $16.3M	05.03.
Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates	05.03.
Gritstone bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Gritstone bio, Inc.

Aktien

A2N4RX

US39868T1051

GRTS

Andere Sprachen

Filter